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PART I: U251MG CELL RADIOSENSITIZATION WITH 8 AND 50 
NM GOLD NANOPARTICLES  
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1. INTRODUCTION 
Modern techniques and knowledge in chemistry and biochemistry allow working 
with matter at a nanoscale level. Regarding medical sciences, such an approach is 
especially beneficial for oncology, where exclusive influence on tumor cells spread in 
normal tissues can provide necessary conditions for cancer treatment (Cuenca et al 2006, 
Rao 2008, Cai et al 2008). When the size of cells is scaled in µm, we need even smaller 
agents working at the level of organelles or even the molecular level for selective cancer 
cell therapy; and such intervention has to be more intelligent than just physical or 
chemical influence. Thus, without interfering at the nanoscale level, modern oncology 
with its latest surgical techniques, newly developed advanced chemotherapy agents and 
various radiation sources, fails to cure patients with certain types of malignant tumors.  
  In neuro-oncology, such nanoscale influence is vital for the treatment of 
gliomas, and especially GBM (grade IV glioma, according to World Health 
Organization classification), the most malignant glioma, characterized by fast and 
invasive growth (Guillamo et al 2001, Lefranc et al 2005, Furnari et al 2007). It is 
among those incurable cancers with poor quality of life and poor prognosis, and most 
GBM patients die of their disease with a median survival of one year, despite using all 
modern treatment modalities (Lefranc et al 2005, Hoelzinger et al 2007, Matsuda et al 
2011). As radiotherapy remains one of the most commonly used adjuvant modalities in 
glioma treatment, the realization of a nanoscale influence might be connected with the 
use of nanoparticles not only as carriers of medical drugs or antibodies, but also as 
radiosensitizers - enhancers of the ionizing radiation effect within tumor cells (Carter et 
al 2007, Cai et al 2008, Rahman et al 2010, Jelveh and Chithrani 2011). 
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Radiosensitization was established long before the development of 
nanotechnology. Thus, the difference in the absorbed dose in biological tissues after X-
ray irradiation was observed at the interface of materials with different atomic numbers 
(Z) (Spiers 1949). An additional effect of radiation was also found in tissues with X-ray 
contrast agents (Adams et al 1977, Callisen et al 1979, Santos Melloet al 1983), and it 
was suggested that certain compounds could be used to locally enhance the radiation 
dose. Different non-metallic chemical substances were tested for radiation enhancement 
(Biaglow et al 1983, Nath et al 1990, Murayama et al 1993, Nishioka et al 1999, 
Shibamoto et al 2001), as well as X-ray contrast agents, mainly based on iodine 
(Matsudaira et al 1980, Fairchild et al 1983, Rose et al 1999, Karnas et al 1999, Robar 
et al 2002, Corde et al 2004, Boudou et al 2005, Esteve et al 2006, Adam et al 2006).  
Recent studies on dose perturbations at interfaces with high-Z materials in kilovoltage 
and megavoltage photon beams (Das and Kahn 1989, Das and Chopra 1995) and more 
relevant secondary radiation from metallic gold surfaces at the interface with biological 
structures (Regulla et al 1998 and 2002) showed higher potential of high-Z metals, and 
especially gold, in comparison with non-metallic compounds. In this regard, golden 
microspheres were introduced as biologically effective radiosensitizers (Herold et al 
2000), and with the development of nanotechnology, nanoparticles made of materials 
with different atomic numbers (25 to 90) were tested for radiosensitization (Roeske et al 
2007).   
Gold has certain advantages in comparison with other radiosensitizers, such as 
iodine or gadolinium (Cho 2005), which have already been approved and used in 
clinical practice as contrast agents. Gold nanoparticles can provide a higher degree of 
radiation enhancement with relative chemical inactivity in living organisms, which 
predetermines higher doses of gold used within the safety level (Cai et al 2008, Jelveh 
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and Chithrani 2011). Radiation enhancement using GNPs is mainly determined by 
Auger electrons and secondary (fluorescent) photons emitted from the irradiated 
particles. For such interactions tumor cells containing GNPs should be irradiated with 
X-ray photons with energies over those of the inner K (68.0–80.7 keV), L (L1 14.4 keV; 
L2 13.7 keV; L3 11.9 keV) and M (2.2–3.4 keV) gold atomic shells, which are 
sufficient to eject electrons from the mentioned orbits (Figure 1) (Leung et al 2011). As 
such reactions are related to photon capture by gold atoms, therapy using this method 
can be defined as a photon capture therapy (PCT). The influence of X-rays on GNP-
containing tumor cells can be described in several parallel and consecutive processes 
(Figure 2), which include electron and photon emission from irradiated GNPs (direct 
influence) and the production of free radicals from GNPs-emitted photons and electrons 
(indirect influence) (Han et al 2010, Jelveh and Chithrani 2011). 
The plasticity of gold as a main component of nanoparticles enables the 
production of nano-sized structures of different forms, including gold nano-rods, nano-
cages, and nano-shells (Wei and Zamborini 2004, Rodriguez-Fernandez et al 2005, Cai 
et al 2008, Jelveh and Chithrani 2011). In comparison with such structures, round-
shaped GNPs are most commonly used in oncological research mainly because of their 
relatively easy production, lower toxicity and greater capacity for functionalization (Cai 
et al 2008, Chithrani et al 2006, 2010 and 2011, Pan et al 2007, Rahman et al 2009, 
Butterworth et al 2010)  
Therefore, in our study we tested the radiosensitization efficacy of round-shaped 
GNPs on human U251MG cells. We used 8 nm GNPs, as <10 nm particles were 
theoretically described as capable of tumor cell nuclei penetration (Chithrani et al 2010), 
and 50 nm GNPs, as particles of such size were reported to be best accumulated by 
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tumor cells (Chithrani e al 2006 and 2010). Parameters such as light absorption, 
cytotoxicity and uptake by tumor cells, were also evaluated. 
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2. STUDY OBJECTIVES 
1. Evaluate optical properties of 8 and 50 nm GNPs in PBS solution based on light 
absorption characteristics. 
2. Determine intracellular localization, cytotoxicity and cellular uptake of 8 and 50 
nm GNPs in human U251MG cells. 
3. Evaluate radiotherapy the enhancement effect of GNPs in different 
concentrations in human U251MG cells. 
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 3. MATERIALS AND METHODS 
3.1 Gold nanoparticles 
Colloidal solutions of oligoglycine-stabilized 8 and 50 nm GNPs containing 750 
and 500 ppm of gold, respectively, were purchased from Winered Chemical, Inc., 
Tokyo, Japan (http://www.winered.jp). The particles were produced by the method 
described elsewhere (Watabe 2005). The size of GNPs was declared by the 
manufacturer. The light absorption was estimated on a UV-2501 PC
®
 optical analyzer 
(Shimadzu Co. Ltd., Kyoto, Japan). The amount of gold in the particle colloidal solution 
was reassessed by the inductively coupled plasma mass-spectrometry (ICP-MS). GNPs 
were maintained in sterile tubes at 4°C. 
3.2 U251MG cell line 
Human U87MG cells were obtained from ATCC and cultured at 37°C in a 
humidified atmosphere of 5% CO2 in MEM (M4655, Sigma-Aldrich, MO, USA) 
supplemented with 10% fetal bovine serum (FBS; JRH Nichirei Biosciences, Tokyo, 
Japan) and 1% penicillin-streptomycin (100 U/ml penicillin, 0.1 mg/ml streptomycin, 
Sigma-Aldrich, MO, USA).  
3.3 X-ray source 
The Hitachi MBR-1520R biological X-ray irradiator, operated at 150kVp and 
20mA, was calibrated using  an AE1341-D ionizing chamber (Applied Engineering, 
Inc., Tokyo, Japan) and GD-352M glass dosimeters (AGC Techno Glass Co., Ltd., 
Chiba, Japan), analyzed by a KXO-50XM X-ray diagnostic system (Toshiba Medical 
Systems, Co.). Glass dosimeters were placed in the center and 40 mm from the center of 
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the rotating table, at a distance of 350 mm from the X-ray tube; dosimetry results were 
further used for dose adjustment. The spectrum of the irradiator was simulated by 
SpekCalc® software using Poludniowsky algorithm (Poludniowsky et al 2007, 2009) 
(Figure 3). 
3.4 Transmission electron microscopy 
The size and localization of GNPs in U251MG cells were studied using a JEM-
1400 transmission electron microscope (JEOL Ltd., Tokyo, Japan) operated at an 
accelerating voltage of 120 kV. U251MG cells were incubated with 8 and 50 nm GNPs 
at a gold concentration of 15 µg/ml during 24 h. After incubation, cells containing 
nanoparticles were washed twice with PBS, centrifuged, fixed and submitted for further 
processing. The samples were mounted on copper grids, placed into the TEM. The 
images were analyzed to determine the particle size and intracellular localization.  
3.5 Cytotoxicity assay 
The cytotoxicity evaluation was performed to show the decrease in cell 
proliferation after incubation with GNPs in order to determine the maximum gold 
concentration in the medium applicable for further experiments. In short, 100 µl of 
MEM with 8000 of U251MG cells was placed in each well of 96-well plates and 
incubated for 24 h. The medium was replaced by MEM with GNPs (15 - 150 µg 
gold/ml) and further incubated for 24 h. Then, the medium containing GNPs was 
removed, and the cells were washed twice with PBS. 2 ml of a 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) solution 
with PMS (Cell Titer 96® AQueous One Solution, Promega, WI, USA) were mixed 
with 10 ml of MEM, and added in the amount of 100 µl to each well. The cells without 
GNPs were used as controls. The plates were incubated and the absorption at 490 nm 
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was assessed using a Mithras LB 940 Multimode reader (Berthold Technologies, 
Germany) after 2 h. As GNPs are visually non-transparent and may disturb light 
absorption, the wells containing cells with GNPs without MTS solution were used as 
additional controls. 
3.6 Gold accumulation by U251MG cells   
The accumulation of gold in GNPs by the tumor cells was assessed with the 
ICP-MS (ICP-8100MS, Shimadzu, Kyoto, Japan) according to the protocol, modified 
from the methods described elsewhere (Martin de Llano et al 1996, Scheffer et al 2008, 
Allabashi et al 2009, Furuyama et al 2009 and Judy et al 2011). In short, after the 
incubation in 4 ml of MEM with GNPs at different concentrations (15 - 45 µg gold/ml) 
the cells were washed twice with PBS, detached from the flasks with 0.05% trypsin-
EDTA (Nacalai Tesque, Inc., Japan), counted, and heated at 120°C in the concentrated 
nitric acid for 2 h. The necessary amount of the hydrochloric acid was added to obtain 
Aqua Regia to dissolve gold. The solution was diluted with distilled water, filtrated with 
50 µm filters and submitted for the ICP-MS. The amount of gold was recalculated for 
10
6
 cells. 
3.7 Radiation treatment & Colony forming assay 
U251MG cell survival after X-ray irradiation was assessed by colony forming 
assay. Initially, U251MG cells were seeded at a concentration of 10
6
 cells per flask and 
incubated for 24 hours. 8 or 50 nm GNPs were diluted in MEM to the gold 
concentrations of 15 µg/ml, 30 µg/ml and 45 µg/ml, the medium in the flasks was 
replaced with a new medium containing GNPs, and the cells were further incubated 
during 24 h. After incubation, the cells were washed twice with PBS, separated into 
different plastic tubes according to the gold concentration and irradiation dose, and 
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irradiated with 2, 4 and 8 Gy. Treated-with-GNPs unirradiated cells, untreated irradiated 
and untreated unirradiated cells were used as controls. After irradiation, U251MG cells 
were diluted and placed into round plates according to the irradiation dose and the 
concentration of GNPs, and incubated for 14 days. After incubation, cells were fixed 
and stained with 0.2% crystal violet. The plates were scanned and the colonies of over 
50 cells were counted using Biozero® software (Keyence, IL, USA). 
3.8 Evaluation of radiobiological parameters 
All the experiments were repeated at least 3 times each; colony forming assay 
results were summarized from at least four independent experiments. The cytotoxicity, 
gold accumulation and cell survival data represent means ± SDs, p-values were 
calculated by one-way ANOVA. In the colony forming assay, the cell survival fraction 
(SF) was calculated as follows: 
   
                                              
                     
, 
 where the plating efficiency (PE) was obtained from the equation:  
   
                               
                  
   
To determine the linear parameter α and the quadratic parameter β, the cell survival 
curves were fitted by a weighted, stratiﬁed, linear regression function in SPSS 18.0 
(PASW Statistics 18, IBM, NY, USA) according to the linear–quadratic formula:  
           
  , where D is the irradiation dose, using the protocol, adapted from 
elsewhere (Franken et al 2006). In the regression, SF was assigned as a dependent 
variable, D and D
2
 as independent variables, and the statistical weight was estimated as 
follows: 
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. 
Statistical errors of α and β were calculated with 95% confidence intervals. Using α and 
β values such parameters as SF2 dose and D10 were calculated for each gold 
concentration and irradiation dose by solving the quadratic equation: 
                 
where a=α, b=β, c=ln(SF), and x represented the dose and equaled: 
  
   √      
  
; 
positive values of x were used. SF2 dose represented the irradiation dose delivered to the 
cells with GNPs needed to obtain the same surviving fraction as 2 Gy irradiation given 
to the cells without GNPs, and D10 was the dose needed to achieve 10% of the cell 
survival. Dose enhancement factors were calculated as ratios of the control parameters 
to the treatment parameters. Thus, DEF (SF2) was the ratio of the control 2 Gy to the 
SF2 dose, and DEF (D10) was the D10 ratio between the controls and cells with GNPs. P-
values (SF2 fit.) were calculated from the fitted values of SF2. AUC was the area under 
each fitted LQ model curve, and was calculated to determine the statistical significance 
between the control and treatment curves as a definite integral of the linear quadratic 
function: 
    ∫              
 
 
  
DEF (AUC) was the AUC ratio between the control and treatment curves, x was the 
dose. 
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4. RESULTS 
4.1 Light absorption by GNPs 
Normalized light absorption spectra of 8 and 50 nm GNPs colloidal solutions are 
presented in Figure 4. There are single peaks for each type of particles with the 
maximum light absorption at 522 nm for 8 nm GNPs and 530 nm for 50 nm GNPs, and 
the narrower peak of 50 nm GNPs.  
4.2 Transmission electron microscopy  
On TEM images, 8 nm and 50 nm GNPs were clearly seen in the cytoplasm of 
glioma cells (Figure 5A,B). The 8 nm particles looked more uniform in their size and 
more intense accumulation in tumor cells was observed; it was clearly seen that the cells 
captured 8 nm particles into vesicles. The diameter of larger GNPs varied; both types of 
particles were seen only in the cytoplasm of the examined cells, without obvious nuclei 
penetration. 
4.3 Cytotoxicity of gold nanoparticles 
The decrease in proliferation of U251MG cells was related to the concentration 
of GNPs in the medium (Figure 6). The concentration of 15, 30 and 45 µg gold/ml of 
both types of GNPs did not significantly reduce cell proliferation compared to the 
control. The presence of 8 nm GNPs in concentrations over 45 µg gold/ml significantly 
decreased cell proliferation; the proliferation of cells containing 50 nm GNPs did not 
significantly differ from the control within the studied gold concentration range (15-150 
µg gold/ml). For 8 nm GNPs, cell proliferation decreased from 68±11% at 60 µg 
18 
 
gold/ml to 30±18% at 150 µg gold/ml. The concentration of 15, 30 and 45 µg gold/ml 
of both GNPs was used in further experiments. 
4.4 Accumulation of gold by the tumor cells 
The amount of gold accumulated in 10
6
 of U251MG cells evaluated by the ICP-
MS is presented in Figure 7. Gold accumulation varied depending on the initial GNPs 
concentration in the medium. Thus, at 15 µg gold/ml in MEM larger 50 nm GNPs 
showed 1.27 times higher gold accumulation than 8 nm GNPs (17.11±1.26 versus 
13.50±0.49, p=0.01). At higher concentrations, cells with 8 nm GNPs showed higher 
gold accumulation. Thus, at 30 µg gold/ml 8 nm GNPs showed 1.31 times higher gold 
accumulation than 50 nm GNPs (37.66±1.61 versus 28.72±0.41, p=0.001) and at 45 µg 
gold/ml 1.30 times higher gold accumulation (53.74±2.79 versus 41.43±0.88, p=0.001).  
4.5 Glioma cell survival and dose enhancement 
Colony forming abilities of U251MG cells were assessed in 10 consecutive X-
ray irradiation experiments, and the normal survival data (without GNPs) were fitted to 
the LQ model using the regression function, as described in Materials and Methods, and 
presented in Figure 8. The parameters α and β were determined from the curve fit as 
0.196±0.002 and 0.027±0.0004, respectively. Using these parameters the dose needed 
for 10% cell survival (D10) was calculated and equaled 6.132±0.694 Gy. The area under 
curve (AUC) was evaluated to compare the difference between the treatment and 
control curves (Figure 9) and equaled 2.897±0.431 (the relative area). The survival 
curves of glioma cells with GNPs were estimated using the data of at least 4 
experiments, fitted similarly to the control and presented in Figures 10 A, B. The 
parameters α and β, SF2 doses, D10, AUCs, DEFs and the p-values of the control and 
treatment groups of cells are arranged in Table 1. 
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5. DISCUSSION 
5.1 Optical properties of GNPs 
Optical properties of GNPs in colloidal solutions obtained from Winered 
Chemical laboratory were studied to verify the presence of nano-sized particles and 
their stability in the solution before using them in experiments on cells. The presence of 
nano-sized particles in the solution was confirmed by the spectrum of light absorption 
with an obvious peak at a certain wavelength for each particle type (522 nm for 8 nm 
GNPs and 530 nm for 50 nm GNPs, Figure 4). The formation of the absorption peak is 
determined by a well-known phenomenon called plasmon resonance, which is related to 
the presence of surface electromagnetic waves at the interface of a metal and dielectric 
material (Bohren and Huffman 1983, Kreibig and Vollmer 1995). The essence of this 
phenomenon is the resonance of the internal collective oscillations of electrons in metal 
with the oscillations generated by the electromagnetic wave spreading in the medium 
(water solution, or PBS in our case). The plasmon absorption band emerges when the 
size of particles becomes smaller than the length of the free pass of free electrons in the 
metallic mass (several nanometers to several tens of nanometers). The scattering of free 
electrons takes place mainly at the surface of particles, therefore the plasma frequency 
of free oscillations of electrons shifts from the UV range to the visible light spectrum, 
and we can see the peak of absorption if there are nanoparticles in the solution. Thus, 
with the presence of single peaks for each type of GNPs at the different wavelengths, 
we confirmed that we had stable colloidal solutions of nanoparticles with different sizes, 
suitable for further cell experiments, and the narrower peak of 50 nm GNPs represented 
more uniform particle size distribution.   
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5.2 Size and localization of GNPs in tumor cells 
Visualization with TEM confirmed the ability of the tumor cells to capture 
GNPs by the elongations, and both 8 and 50 nm GNPs were clearly seen in the 
cytoplasm of U251MG cells (Figure 5 A, B). It is considered that smaller < 10 nm 
GNPs have a potential to penetrate the nuclei of cells, providing better opportunities for 
radiation therapy when located close to the DNA (Chithrani et al 2010). Nevertheless, 
both types of GNPs were well observed in the vesicles within the cell cytoplasm, 
without obvious nuclei penetration, as it was not clearly seen if single particles were 
separated from the clusters and located in other cell organelles or penetrated the nuclei. 
The use of GNPs < 8 nm could theoretically increase the probability of nuclei 
penetration, though even smaller sizes of particles may lead to a significant decrease in 
the cell uptake, determining the necessity of using particle carriers, such as liposomes, 
to achieve essential accumulation in cells (Chithrani et al 2010). The size of particles 
was also evaluated using TEM, though the most contrasting part of a particle was the 
central cluster of gold atoms, and the outer layer of the stabilizing compound might not 
be clearly visible. 
5.3 Composition and cytotoxicity of GNPs  
To be used in living organisms for radiation enhancement, nanoparticles need to 
combine high radiosensitization properties with biocompatibility. Among different 
forms, spherical nanoparticles were most commonly used by researchers in the field of 
medical physics and oncology, because of stability and relative biological inertness of 
such nanostructures (Chang et al 2008, Kim et al 2010, Chithrani et al 2010, Jain et al 
2011). There are several reasons for using spherical GNPs, and the first one is the 
easiest way of particle production, where in many cases gold is stabilized by the salts of 
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citric acid, or citrates (Cai et al 2008, Hainfeld et al 2004, 2006, 2008 and 2010, 
Chithrani et al 2006 and 2010, Butterworth et al 2010, Chithrani 2011), and the size of 
particles depends on the amount of ionized gold included in the chemical reaction. 
Another reason to use a spherical shape may be connected with the intention to reduce 
the toxicity of GNPs. In contrast to previous suggestions about the absolute inertness of 
gold in biological systems, recent studies have shown structure- and size-dependent 
toxicity of GNPs (Pan et al 2007, Butterworth et al 2010, Jain et al 2011, Trono et al 
2011). Finally, the spherical shape provides the possibility to uniformly cover the round 
particle surface with active compounds, such as polysaccharide molecules, medical 
drugs, antibodies or fluorescent components, for specific targeting of cells or tissues 
(Chen and Zhang 2006, Kong et al 2008).  
In our study, we used oligoglycine-stabilized spherical GNPs, which showed 
size-dependent cytotoxicity (Figure 6). According to the literature data, the cytotoxicity 
of gold nanoparticles depends on their size and their concentration in the medium (Pan 
et al 2007, Butterworth et al 2010). Nevertheless, 50 nm GNPs were not toxic for 
U251MG cells within the studied concentration range, whereas 8nm GNPs decreased 
cell proliferation significantly at concentrations over 45 µg/ml. Thus, only 8 nm 
particles corresponded to the concentration-dependent cytotoxicity model.  
We assumed that, in the case of spherical GNPs, the toxicity might be related to 
the potential presence of a layer of ionized gold, located between the inert metallic 
golden core with 0-valency and the layer of the stabilizing component (e.g., citrate or 
amino-acid layer). Thus, the toxicity may depend on the surface reactivity, related to the 
ability of the non-reactive surface layer to hide the reactive ionized gold. Therefore, in 
our experiments larger 50 nm GNPs could be less toxic due to the thicker layer of 
glycine oligopeptide on their surface hiding the reactive ionized gold.  
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It could also be possible to use the additional toxic effect of 8 nm GNPs in 
cancer therapy, though specific protection of normal cells would be needed, such as 
encapsulation of such particles into liposomes or other carriers, and even in that case it 
would be risky for normal tissues. So such an approach requires further investigation.   
The non-toxic gold concentration range was assigned as 15 to 45 µg/ml, and all 
further experiments were performed using these concentrations. In regard to the atypical 
cytotoxicity results, we can suggest, that not only size, but the composition of GNPs 
may play a role, as well as other factors yet to be studied.  
5.4 Accumulation of GNPs by U251MG cells  
According to the literature data, 50 nm GNPs show the highest cell accumulation 
(Chithrani et al 2006). Nevertheless, in our study the accumulation of GNPs varied 
depending on the initial concentration in MEM (Figure 7). Thus, 50 nm GNPs showed 
better cell uptake at 15 µg/ml, and 8 nm GNPs showed better cell uptake at 30 and 45 
µg/ml. There could be some relationship between higher accumulation of 8 nm gold 
nanoparticles in cells (at 30 and 45 µg/ml) and their higher cytotoxicity level. Thus, 
more detailed studies are required to determine such a relationship.  
We suggest that not only size, but the combination of factors, including form, 
size and composition of GNPs, might be responsible for particle accumulation in vitro. 
Moreover, in vitro experiments can only partially correspond to animal tumor models, 
and in some cases do not represent the real state of events. The enhanced permeability 
and retention (EPR) effect contributes to the delivery of GNPs to the tumor tissue 
through leaky tumor vessels (Dvorak et al 1988, Maeda et al 2000, Furuyama et al 
2009). We suggest that the presence of GNPs around the tumor cells in the animal 
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model or in real clinical conditions can be provided mostly by particle functionalization, 
leading to targeted delivery.  
5.5 X-ray irradiation source and photon capture by GNPs 
Energies necessary to induce the GNPs-related radiotherapy enhancement were 
described according to theoretical calculations and computer software simulations 
(Leung et al 2011, Brun et al 2009, Montenegro et al 2009, Pradhan et al 2009). In most 
cases, the photon capture and electrons/photons emission takes place when the initial X-
ray influence is provided within the kilo electron volt (keV) energy range. The influence 
of higher photon energies, e.g. within the mega electron volt (MeV) range, initiates 
different processes, mainly connected with photon scattering, and the radiation 
enhancement effect is lower than that at the keV-irradiation (Jain et al 2011, Leung et al 
2011). And within the keV range the influence on Kα-edge with the energy of 68 keV 
or slightly higher was suggested to be more efficient for GNPs-related radiosensitization 
(Montenegro et al 2009, Pradhan et al 2009). 
The irradiation source we used could provide only a limited amount of photons 
in the effective energy range, as the conventional X-ray tube contained a wide spectrum 
of photon energies (Figure 3). Nevertheless, it is possible to determine the most 
advantageous irradiation energies according to the X-ray mass attenuation coefficients 
of gold and other materials presented by the US National Institute of Standards and 
Technology (http://www.nist.gov/pml/data/xraycoef/index.cfm). We studied the 
compliance of the spectrum of Hitachi MBR-1520R biological X-ray irradiator, 
designed by SpekCalc® software using Poludniowsky algorithm (Poludniowski et al 
2007, 2009), with the energies needed to eject electrons from gold atom inner shells. 
Thus, in our case the effective parts of the spectrum with the excess of energies of the 
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initial photons over that of K-, L, and M-shells represent the potential energy of 
secondary photons, emitted by gold atoms, as well as the pathway length of ejected 
Auger electrons. 
GNPs absorb a portion of the initial X-rays and emit low energy electrons and 
secondary (fluorescent) photons, which were previously found to damage DNA and the 
cell microenvironment (Boudaiffa et al 2000, Sanche 2002, Brun et al 2009). Indirect 
damage to DNA and the cell organelles by free radicals (mainly OH*), produced from 
GNPs-emitted low energy electrons and photons interacting with water molecules may 
also take place, as such interactions were discovered long before the invention of GNPs 
(Chatterjee and Magee 1985) and further investigated in recent years (Sanche 2009, 
Wang et al 2009). When local interactions take place within micrometers, secondary 
photons and electrons have the potential to damage cell DNA or other cell components, 
such as cell membranes (e.g., through lipids peroxidation). Nevertheless, if the initial X-
ray energy is low, the secondary processes may take place within nanometers, and to 
damage DNA GNPs need to be located in close proximity to chromosomes, very close 
or within the cell nucleus, which can theoretically be achieved only by using very small 
< 10 nm particles. However, very small (several nm) size of GNPs may lead to decrease 
in particle uptake and higher toxicity; so particle incorporation in larger carriers, such as 
liposomes, would be required (Chithrani et al 2010). 
5.6 Glioma cell radiosensitization and dose enhancement factors 
Survival data of irradiated U251MG cells showed the typical influence of 
ionizing radiation on the colony forming abilities of tumor cells with the compliance of 
fitted curves to the LQ model (Figure 8). The linear-quadratic model was first proposed 
by Douglas and Fowler (1976) and now is the most commonly used model to describe 
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the effect of ionizing radiation on cells. In such a representation, the single destructive 
event or influence of radiation is described by the alpha-parameter, which is linearly 
related to dose, and the two-stage mechanism of DNA destruction is related to the 
square of the dose (beta-parameter). Therefore, the linear quadratic model corresponds 
to double strand DNA breaks, which are responsible for cell destruction by ionizing 
radiation. The use of the linear-quadratic model is described in the classical protocol of 
colony forming assay, which was used in our study (Franken at al., 2006). The curve fit 
allowed determination of the linear parameter α and the quadratic parameter β, which 
characterized the exponential decrease in cell survival after irradiation in small doses, 
and to evaluate the significance of differences between the treatment and control curves 
finding AUC - the area under the LQ fitted curves (Figure 9). We observed that X-ray 
irradiation with 8 Gy within the spectrum of MBR-1520R biological irradiator in 
combination with 8 nm GNPs in the concentration of 45 µg/ml and 50 nm GNPs in 
concentrations of 30 and 45 µg/ml could provide effective tumor cell growth control 
(Figure 10 A, B). To analyze the additional effect of secondary radiation from GNPs 
and calculate dose enhancement factors (DEFs), such parameters as the dose needed for 
10% cell survival and the SF2 dose were calculated using α and β values (Table 1), as 
described in the literature (Butterworth et al 2010, Jain et al 2011).  In our study we 
used radioresistant p53-mutant human U251 malignant glioma cells, which are 
characterized by p53-independent apoptosis (Afshar et al 2006) and cell cycle arrest 
was observed after irradiation. As p53-independent apoptosis is more prominent after 
irradiation with higher doses (Merritt et all 1997), we observed insignificant differences 
between 2 Gy irradiation values of the control and treatment groups using both types of 
GNPs (Figure 10 A, B). Similarly, SF2 dose values and the corresponding dose 
enhancement factors DEF (SF2) were found not significant, whereas D10, AUC and the 
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corresponding DEF (D10) and DEF (AUC) values were found to be statistically reliable 
factors to assess radiation enhancement (Table 1). AUC and the corresponding DEF 
(AUC) values represented the general behavior of the cell survival curves within the 
irradiation range (0 - 8 Gy). D10 and DEF (D10) were found statistically more significant 
than other parameters, as p-values were lower than those for other radiobiological 
parameters (Table 1). From the experimental data, effective radiosensitization of glioma 
cells was achieved at 8 Gy of keV-X-ray irradiation of the cells with 8 nm GNPs using 
45 µg gold/ml in the medium (p=0.024); 50 nm particles showed more significant 
radiosensitization at 8 Gy with 30 µg gold/ml (p=0.006) and 45 µg gold/ml (p=0.006) 
(Figure 10 A, B).  
Based on gold accumulation and cell survival data we can summarize that at 
least 8 Gy X-ray irradiation of glioma cells containing at least 53.7 µg of gold per 106 
cells in the form of 8nm GNPs and 28.7-41.4 µg of gold per 106 cells in the form of 
50nm GNPs can provide tumor growth control. Due to the toxicity of 8 nm GNPs, 50 
nm GNPs are more suitable for radiosensitization and eligible for further studies. 
Our work clarified certain processes that happen when gold nanoparticles are 
accumulated by tumor cells and irradiated with X-rays. We believe that the results of 
our study will be useful for other researchers in the same field and may help further 
development of cancer radiotherapy. 
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6. CONCLUSION 
1. 8 nm and 50 nm GNPs were present in stable colloidal solutions and showed 
optical properties typical for nano-sized spherical particles. 
2. Both types of GNPs were captured by U251MG cells by the invaginations of the 
cell membrane, and clustered into vacuoles in the cytoplasm of glioma cells, 
without obvious nuclei penetration. 
3. Both types of GNPs were well accumulated in U251MG cells: smaller 8 nm 
particles showed higher cytotoxicity, whereas 50 nm GNPs were non-toxic 
within the studied concentration range (15 - 150 µg/ml).   
4. Both types of GNPs provided radiotherapy enhancement for human U251 
malignant glioma cells at certain concentrations (at 45 µg/ml of 8 nm particles 
and 30 - 45 µg/ml of 50 nm particles) irradiated with 8 Gy of 150 kVp X-rays; 
for p53-mutant U251MG cells, D10 and AUC were found to be statistically 
reliable parameters to evaluate dose enhancement. 
5. 50 nm GNPs might have a higher potential in glioma radiotherapy enhancement, 
and further studies in this area, including active tumor targeting with GNPs, are 
required to evaluate the efficacy of this method.  
 
  
 
 
 
 
 
PART II: HYALURONIC ACID-MELANIN-BASED GNPS  
29 
 
7. INTRODUCTION 
Cancer diagnosis and therapy can be better provided using functionalized agents, 
aimed to target specific cells, tissues or organs. Such an approach is suggested to be 
more beneficial than the enhanced permeability and retention (EPR) effect, which 
contributes to non-specific accumulation of nanoparticles in tumor cells through 
fenestrated tumor vessels (Dvorak et al 1988, Maeda et al 2000, Furuyama et al 2009). 
Additionally, fixation of nanoparticles in the tumor tissue after targeted delivery might 
prolong the effect of therapy and contribute to better prognosis.  
In this regard, we proposed the use of melanin and hyaluronic acid, included into 
the particle composition, to improve the functional potential of GNPs (Figure 11). 
Melanin molecules can bind to and imbed a large number of gold atoms, providing high 
gold concentration relative to other compounds, and hyaluronic acid (HA) is designed to 
provide fixation in tissues and local capture by tumor cells by attaching to CD44 
receptors (Choi et al 2012). Therefore, HA might be responsible for prolonged 
localization of gold atoms in the tumor tissue providing their gradual distribution. Such 
an approach can be used both in diagnosis and therapy of malignant tumors. 
We suggest that high molecular HA-melanin-based GNPs be used for local 
application, because of their high viscosity and high affinity to connective tissues, 
whereas low molecular HA characterized by low viscosity can be used in GNPs for 
systemic intravenous application.  
In the present study we examined the structure, chemical composition and 
cytotoxicity of HAMG-NPs, as well as their X-ray contrasting properties and their 
prospective application as a CT contrast agent, using human U251MG cells and the 
nude mouse flank tumor model. 
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8. STUDY OBJECTIVES 
1. Evaluate optical properties of hyaluronic acid-melanin-based (HAMG) NPs 
based on light absorption.  
2. Determine intracellular localization of HAMG-NPs in tumor cells and their 
toxicity. 
3. Analyze X-ray contrasting properties of hyaluronic acid-melanin-based GNPs. 
4. Evaluate dose enhancement after local injection into U251MG animal model. 
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9. MATERIALS AND METHODS 
9.1 HAMG-NPs 
Colloidal solutions of hyaluronic-acid-melanin-based GNPs containing 5000 
ppm of gold were obtained from the International research center “Martinex”, Moscow, 
Russian Federation. The particles were produced by a solid-state synthesis and 
modification of polysaccharide-based polymers. The light absorption was estimated on 
a UV-2501 PC
®
 optical analyzer (Shimadzu Co. Ltd., Japan). Size and localization of 
GNPs in U251MG cells were studied using the BioZero
®
 BZ-8000 optical system 
(Keyence, IL, USA) and the JEM-1400 transmission electron microscope (JEOL Ltd., 
Tokyo, Japan). The particles were maintained in sterile tubes at 4°C. 
9.2 U251MG cell line 
Human U87MG cells were obtained from ATCC and cultured at 37°C in a 
humidified atmosphere of 5% CO2 in MEM (M4655, Sigma-Aldrich, MO, USA) 
supplemented with 10% fetal bovine serum (FBS; JRH Nichirei Biosciences, Tokyo, 
Japan) and 1% penicillin-streptomycin (100 U/ml penicillin, 0.1 mg/ml streptomycin, 
Sigma-Aldrich, MO, USA). 
9.3 U251MG animal model 
The flank tumor model was obtained by a subcutaneous injection of 5x10
6
 
U251MG cells in the left thigh of Balb/C nude mice. The cells were suspended in 0.05 
ml of equal volumes of MEM and Matrigel. The tumor volume was estimated as a half 
of the small diameter squared times the large diameter. Tumors over 100 mm
3
 were 
defined as eligible for the local GNPs injection. The use of animals was approved by the 
ethical committee. 
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9.4 Cytotoxicity assay 
The cytotoxicity analysis was performed to show the cell proliferation after 
incubation with GNPs and to determine the maximum gold concentration in the medium 
applicable for the experiments. 100 µl of MEM with 8000 of U251MG cells was placed 
in each well of 96-well plates and incubated for 24 h. The medium was replaced by 
MEM with HAMG-NPs or HA-Au (Au
+3
) (15 - 150 µg gold/ml) and further incubated 
for 24 h. The medium was removed and the cells were washed twice with PBS. 2 ml of 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) solution with PMS (Cell Titer 96® AQueous One Solution, 
Promega, USA) were mixed with 10 ml of MEM, and added in the amount of 100 µl to 
each well. The cells without GNPs were used as controls. The plates were incubated and 
the absorption at 490 nm was assessed using a Mithras LB 940 Multimode reader 
(Berthold Technologies, Germany) after 2 h. The wells containing cells with GNPs 
without MTS solution were used as additional controls. 
9.5 CT scan 
The X-ray CT scan was performed using a Latheta LCT-100 Lite (Hitachi Aloka 
Medical, Ltd., Japan) CT scanner for small animals, operated at 50kVp. The mice were 
anaesthetized with phenobarbital sodium, 30 mg/kg of body weight. GNPs were 
injected into the tumor tissue in the volume of 50 µl in each of 2 – 3 injections from 
different sides of the tumor. The CT scan was performed before the injection, right after 
the injection and 6 hours after the injection of GNPs. 
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9.6 Transmission electron microscopy 
The JEM-1400 transmission electron microscope (JEOL Ltd., Tokyo, Japan) 
operated at an accelerating voltage of 120 kV was used to analyze the size and 
localization of GNPs in U251MG cells in vitro and the presence and location of GNPs 
in the tumor tissue in vivo. In the experiment in vitro, U251MG cells were incubated 
with HAMG-GNPs at a gold concentration of 15 µg/ml during 24 h. After incubation, 
cells containing nanoparticles were washed twice with PBS, centrifuged, fixed and 
submitted for further processing. In the experiments in vivo, animals were anaesthetized 
and sacrificed, the tumor tissue obtained after the CT scan was cut, fixed and submitted 
for further processing. Samples were mounted on copper grids and placed into the TEM. 
GNPs size and intracellular localization were analyzed using TEM images.   
9.7 Radiation treatment 
Mice in the “irradiation” and the “GNPs+irradiation” groups were anaesthetized 
with phenobarbital sodium (30 mg/kg of body weight) and placed onto a special mouse 
holder plate for the Hitachi MBR-1520R biological X-ray irradiator. Mice bodies were 
shielded with lead except for the tumor region; the plate was placed into the irradiator at 
a distance of 350 mm from the X-ray tube. The dose of 8 Gy was delivered to the tumor 
region with the irradiator operated at 150 kV and 20 mA. 
9.8 Statistical analysis 
The cytotoxicity experiments were repeated at least 3 times each. The 
cytotoxicity and tumor growth data represent means ± SDs, p-values were calculated by 
one-way ANOVA. 
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10. RESULTS AND DISCUSSION 
10.1 Light absorption by HAMG-NPs 
Optical properties of HAMG-NPs in the colloidal solution obtained from 
International Research Center “Martinex” were studied to verify the presence of nano-
sized particles and their stability in the solution before using them in experiments on 
cells and animals. Normalized light absorption spectrum HAMG-NPs colloidal solution 
is presented in Figure 12. Similarly to the previously studied 8 and 50 nm oligoglycine-
coated GNPs, the formation of the absorption peak is determined by the plasmon 
resonance (Bohren and Huffman 1983, Kreibig and Vollmer 1995). The single peak at 
526nm confirmed the presence of nano-sized particles and showed the stability of the 
colloidal solution. The narrow peak represented more uniform particle size distribution. 
10.2 Localization of HAMG-NPs in tumor cells in vitro 
Transmission electron microscopy revealed the localization of HAMG-GNPs in 
U251MG cells in vitro (Figure 13). On TEM images HAMG-NPs were clustered in 
vacuoles and localized in the cytoplasm of glioma cells without obvious nuclei 
penetration, similarly to the previously studied oligoglycine-based 8 and 50 nm GNPs. 
The location of particles in close proximity to the cell nuclei may play a role in the 
DNA damage by secondary photons and electrons. Free radicals in this case may play a 
role in the oxidation of lipids and further destruction of membrane structures of tumor 
cells. 
10.3 Composition and cytotoxicity of GNPs 
The biocompatibility of GNPs may play the main role in the selection of certain 
types of particles to be used in living organisms. Spherical nanoparticles may show 
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better biocompatibility, than other structures, because of their form and the uniform 
outer layer of the stabilizing agent, though certain peculiarities of particle composition 
may increase their toxicity. As mentioned earlier, the toxicity may be connected with 
the amount of ionized gold in the outer layer of the spherical particles. In our study, we 
compared the cytotoxicity of HAMG-NPs with the HA-Gold (Au
3+
) solution (Figure 
14). The MTS assay showed a very high toxicity of the ionized gold, and relatively non-
toxic nanoparticles, where gold is covered by the layer of HA and the layer of melanin, 
which stabilized the ionized gold to the 0-valency (Figure 11).    
HAMG-NPs were non-toxic within the studied gold concentration range (15 to 
150 µg/ml), though local and intravenous injections of the same nanoparticle may have 
a different effect on the animal organism.  
In the present study we examined the effects of gold nanoparticles only on tumor 
cells, though the comparison with normal cells would give better understanding of 
further applicability of gold nanoparticles in biological systems, such as animal tumor 
models, and further studies are required to evaluate such applications. 
 10.4 X-ray contrasting properties of HAMG-NPs 
CT scans showed no contrast in the tumor areas before GNPs injection, and 
contrasting of the tumor area right after and 6 h after the injection (Figure 15). The 
character of the contrasting determined the possibility to distinguish the tumor tissue 
from the normal tissue, and showed that the particles could be redistributed within the 
tumor tissue after 6 hours, without being washed out by blood. The CT-scanner was 
operated at 50 kVp. In our consideration, this energy might better comply with the X-
ray absorption by Iodine-containing contrast agents, and the use of energies closer to the 
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inner atomic orbit edges of gold atoms might help to achieve more significant photon 
absorption and better contrasting on CT images. 
10.5 Glioma radiosensitization 
The tumor growth rate in animals with/without treatment using GNPs and 
radiation is shown in Figure 16. The difference between “radiation” and “gold+radiation” 
groups was not statistically significant, though there was a tendency of faster tumor 
growth in mice irradiated without gold nanoparticles. There were several reasons for 
this. U251 malignant glioma showed very slow growth in the current experiment, which 
could influence the results. 2 mice died in the radiation group in the middle of the 
experiment, and the statistical significance decreased. The irradiation with 8 Gy might 
not be enough to interact with tumor cells and gold nanoparticles, and higher doses 
might have a better effect. Local injection of gold might lead to an inhomogeneous 
distribution in the tumor mass and decrease the effect of radiosensitization with gold. 
The flank tumor model might not represent the state of events with the real brain tumor. 
In future studies we should consider these factors to increase the statistical significance. 
We can use a different tumor mode, intravenous injection of gold nanoparticles, a larger 
population and different irradiation doses.  
Concerning radiation enhancement properties, gold is an expensive material and 
is not the only candidate. In this regard, different materials were tested for tumor 
radiosensitization. Among them nicotinamide plus carbogen (Nishioka et al., 1999), 1-
(1′,3′,4′-trihydroxy-2′-butoxy) methyl- 2-nitroimidazole (RP-343), RP-170, etanidazole 
(Murayama et al., 1993); 1-(2′-oxopropyl)-5-fluorouracil (OFU001) (Shibamoto et al., 
2001). A CT contrast agent containing iodine (Z=53) (Adam et al., 2006) was also 
tested for radiosensitization. MRI contrast agents with gadolinium (Z=64) were 
37 
 
similarly suggested for radiosensitization. Nevertheless, the potential effect of higher-Z 
materials such as gold was predicted to be more significant than that of other chemical 
compounds (Hainfeld et al., 2008). We believe that further studies in this area might 
help find a cheaper radiosensitizer with properties close to those of gold nanoparticles. 
In our study we used a keV-radiation source for in vitro and in vivo experiments, 
though in clinical practice MeV-energies are applied to the patients with malignant 
gliomas. According to the literature data, the use of a 6MV X-ray irradiator could 
provide the radiosensitization of breast cancer MDA-MB-231 cells with gold 
nanoparticles with a dose-enhancement factor of 1.29 (p=0.002), the study showed cell-
specific radiosensitization (Jain et al., 2011). The effect of high-energy X-rays can be 
explained by the production of a large number of scattered photons, when MeV-X-rays 
interact with gold nanoparticle. In this process, initial photons possess much higher 
energy than photons in the keV-range observed in the current study. Thus, they can 
interact with several gold atoms, losing their energy and changing direction in the 
matter and producing larger number of secondary photons and electrons. As photons 
lose part of their energy after collision with gold atoms, they can continue their 
pathways in the tissue with energy lower than the MeV-range, e.g. keV-energy, 
producing similar effects as described in the current study. Therefore, we suggest that 
using MeV photons with gold nanoparticles may have prospects in future experiments 
and clinical application.  
Proton radiotherapy may also have potential in the treatment of glioma with gold 
nanoparticle radiosensitization. As was shown by Kim et al. (2010), high-Z particles can 
emit secondary photons and increase the absorption dose after proton irradiation (Kim 
et al., 2010). Similarly to MeV X-rays, protons possess MV energy and can interact 
with high-Z materials. Protons are much bigger than electrons and may collide with 
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several electrons in several gold atoms along their pathway in matter, producing a large 
number of secondary electrons and photons, leading to tumor cell DNA or membrane 
damage. As protons irradiate mainly the area of the main tumor mass if the Bragg’s 
peak is focused on the tumor, other tissues are irradiated in smaller doses, even if they 
contain nanoparticles. Therefore, proton radiation combined with radiosensitization 
using gold nanoparticles may have advantages in comparison with conventional X-ray 
radiotherapy, though further studies are required to evaluate the efficacy of this method. 
10.6 Pathological analysis 
On light microscopy and TEM images of the samples of tumor tissue from the 
animal model, GNPs appeared to be clustered in vacuoles as in U251MG cells 6 h after 
the injection similarly to the in vitro experiments, showing the potential for X-ray 
radiosensitization (Figure 17). GNPs were clearly seen in the tumor cells between the 
muscle fibers after three injections in one week (Figure 18). In this case, the particles 
could be transferred by blood within the tumor tissue and selectively captured by tumor 
cells. Presence of GNPs within the tumor cells in vivo might be related to the properties 
of HA to attach to the tumor cell CD44 and other receptors and be captured into the 
cytoplasm, though these mechanisms are yet to be clarified. 
10.7 GNPs delivery to the tumor cells in vivo 
In this study, we suggest that the particle composition and especially hyaluronic 
acid played a role in the selective and prolonged accumulation of HAMG-NPs in glioma 
cells in vivo. Concerning the delivery of particles to the tumor cells, a number of 
methods and drug-delivery systems have been studied in recent years. One of the 
methods involves the use of liposome carriers to deliver gold nanoparticles to the tumor 
cells. Liposomes are presented as 80–100 nm spherical structures of bilipid membranes 
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which surround the active compounds inside them. Gold nanoparticles may be 
incorporated into liposomes with active molecules, such as polysaccharides or 
antibodies, or both. Liposomes may easily penetrate tumor tissue capillaries because of 
the enhanced permeability and retention (ERP) effect, though smaller single 
nanoparticles may have better penetration abilities. Gold nanoparticles can be 
functionalized similarly to polysaccharides or antibodies, or both. The specificity of 
accumulation of gold nanoparticles in tumor tissues is a challenge for future studies.  
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11. CONCLUSION 
1. HAMG-NPs were present in the stable colloidal solution and showed optical 
properties typical of nano-sized spherical particles. 
2. HAMG-NPs were captured by U251MG cells in vitro, clustered in vacuoles in 
the cytoplasm of glioma cells, without obvious nuclei penetration. 
3. HAMG-NPs provided contrasting of the tumor tissue in vivo right after the 
injection; later they were redistributed in the tumor and captured by tumor cells, 
providing the possibility to be used not only as a contrasting agent for X-ray 
CT but also as radiosensitizers in vivo. 
4. Further studies are required to evaluate the biodistribution of HAMG-NPs and 
their radiosensitization properties in vivo. 
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12. FUTURE PROSPECTS 
Functionalized HAMG-NPs show the ability to be captured by tumor cells in 
vivo after local injection. Though HA may play the role of an active molecule on the 
surface of GNPs, the intravenous injection of HAMG-NPs may lead to an excessive 
load in different organs, such as the liver, where the particles may impair the normal 
function. Although the EPR effect contributes to the diffusion of macromolecules and 
ultrafine materials into the tumor tissue through leaky tumor vessels and within the 
tissues (Dvorak et al 1988, Maeda  et al 2000, Furuyama et al 2009), further 
development of functionalization considers more advanced properties of nanoparticles, 
when, after the targeted delivery, agents can fix to biological structures with or without 
transformation and stay within cells during a certain period of time needed for further 
diagnostic or treatment procedures. The attachment of polysaccharides or antibodies to 
the particles directly or to the outer layer of the particle carriers, e.g. liposomes, was 
found to be effective in achieving higher functionality (Chithrani et al 2010, Liu et al 
2010, Jiao et al 2011, Kumar et al 2012).  Also, such functionality was recently 
demonstrated in studies with targeted GNPs used as X-ray and CT contrast agents 
(Popovtzer et al 2008, Aydogan et al 2010, Reuveni et al 2011).  
Further development of functionalization with the attachment of active 
molecules, such as complex polysaccharides or antibodies, and targeted delivery of 
GNPs, either individually or incorporated in specific carriers such as liposomes, may 
lead to more advanced diagnostic and therapeutic applications of the nanoparticles, not 
only in fundamental research, but also in clinical trials in future. 
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Figure 1  Interaction of X-rays with electrons at the inner glod atomic orbits (schematically). 
Irradiated by photons of a certain energy range gold can emit additional photons and electrons. 
Initial photons knock out electrons at the inner K, L and M gold atomic orbits, the vacant 
places of the missing electrons are occupied by electrons from the higher orbits, and the 
difference in energy is emitted as secondary (fluorescent) photons, accompanied by ejected 
Auger electrons. 
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Figure 2 Direct and indirect damage of tumor cell DNA. Initial X-rays damage tumor cell 
DNA and other components through the direct influence of photons and indirect influence of 
free radicals, formed in the water medium. GNPs capture X-ray photons and emit photons 
and electrons, producing similar direct and indirect damage to the DNA and other cell 
components. DNA damage is mainly caused by HO* radicals, though low energy electrons 
and prehydrated electrons may also be invovlved (Chatterjee and Magee 1985, Boudaiffa et al 
2000, Sanche 2002 and 2009, Brun et al 2009, Wang et al 2009, Han et al 2010). Sample 
DNA helix was designed using Pymol software (www.pymol.org) from the 2L8Q code 
(Julien et al 2011).   
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Figure 3 The Hitachi MBR-1520 biological irradiator spectrum. Calculation was made using 
SpekCalc® software (Poludniowski et at 2007, 2009). The spectrum includes energies over 
K- (68.0–80.7 keV), L- (11.9-14.4 keV) and M-edges (2.2–3.4 keV) of gold atoms, necessary 
to eject electrons from the inner shells, though the resonant influence on the M-shell might 
not be significant. 
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Figure 4 Light absorption by 8 and 50 nm GNPs. Distinguished peaks for each particle type 
at different wavelengths confirm the presence of nano-scaled particles and show the stability 
of the the colloidal solution. The narrower peak of 50 nm GNPs represents more uniform 
particle size distribution.  
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Figure 5A Transmission electron microscopy: the localization of 8 nm GNPs in U251MG 
cells. GNPs are clustered in vacuoles and localized in the cell cytoplasm without obvious 
nucleus penetration. Gold concentration  - 15 µg/ml, 24 h incubation. 
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Figure 5B Transmission electron microscopy: the localization of 8 nm GNPs in U251MG 
cells. GNPs are clustered in vacuoles and localized in the cell cytoplasm without obvious 
nucleus penetration. Gold concentration - 15 µg/ml, 24 h incubation. 
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Figure 6 The concentration- and size-dependent cytotoxicity of GNPs for U251MG cells. 
The cytotoxicity is shown as a ratio of GNPs-containing cell proliferation to the controls 
without GNPs, where the proliferation equals 1 (or 100%), (*p˂0.01; **p≤0.002; 
***p=0.012). The data represent means ± SDs, p-values by one-way ANOVA. 
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Figure 7 Concentration-dependent gold accumulation in U251MG cells. The accumulation is 
shown as the amount of gold (µg) in 106 cells after 24h incubation. The data represent means 
± SDs, p-values by one-way ANOVA. 
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Figure 8 The U251MG cells survival curve (control) fitted to the linear quadratic model. The 
linear parameter α and the quadratic parameter β were obtained from the curve fit according 
to the linear–quadratic formula formula            
  , where D is the irradiation dose (x 
in the equation on the graph). The accuracy of the fit is represented by the R
2
=0.99998. 
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Figure 9 AUC (area under curve) - the area under the fitted LQ model curves. Calculated to 
determine the statistical significance between the treatment curves and the controls as a 
definite integral of the linear quadratic function:     ∫               
 
 
.  
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Figure 10A Survival curves of U251MG cells irradiated with 8 nm GNPs. Irradiation with 2, 
4 and 8 Gy X-rays after 24 hours incubation with 15, 30 and 45 µg/ml of 8 nm GNPs, 
compared to the control. At 8 Gy the difference was found significant at 45 µg/ml (*p=0.024). 
The data represent means ± SDs, p-values by one-way ANOVA. 
 
  
8nm GNPs 
* 
54 
 
Figure 10B Survival curves of U251MG cells irradiated with 8 nm GNPs. Irradiation with 2, 
4 and 8 Gy X-rays after 24 hours incubation with 15, 30 and 45 µg/ml of 8 nm GNPs, 
compared to the control. At 8 Gy the difference was found significant at 30 µg/ml (*p=0.006) 
and 45 µg/ml (**p=0.006).The data represent means ± SDs, p-values by one-way ANOVA. 
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Figure 11 The structure of hyaluronic acid-melanin-based gold nanoparticles (HAMG-NPs). 
The particles contain melanin (empirical formula ), a bioactive component 
stabilizing gold, and modified hyaluronic acid (HA), a matrix carrier for targeted delivery of 
bioactive compounds. 
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Figure 12 Light absorption by HAMG-NPs. The single peak confirms the presence of nano-
sized particles and shows the stability of the the colloidal solution. The narrow peak 
represents the uniform particle size distribution.  
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Figure 13 Transmission electron microscopy: the localization of HAMG-GNPs in U251MG 
cells. GNPs are clustered in vacuoles and localized in the cell cytoplasm without obvious 
nucleus penetration similarly to the previously studied oligoglycine-based 8 and 50 nm GNPs. 
Gold concentration - 15 µg/ml, 24 h incubation. 
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Figure 14 The concentration-dependent cytotoxicity of HAMG-NPs for U251MG cells 
compared to that of the HA-Gold solution, containinag ionized Au
3+
. The cytotoxicity is 
shown as a ratio of GNPs-containing cell proliferation to the controls without GNPs, the 
control cell proliferation equals 1 (or 100%). The data represent means ± SDs, p-values by 
one-way ANOVA. 
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Figure 15 Contrasting properties of HAMG-GNPs. Particles were injected intratumorally 
into the BalbC nude mice U251MG flank model. Mice were anaesthesized and examined at 
the Latheta LCT-100 Lite X-ray CT scanner. 6 hours after GNPs injection the contrast 
distributed within the tumor tissue. 
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Figure 16 U251MG flank model growth in four studied groups of mice. Stages of 
experiements and the aspects of the in vivo study are also presented. The tumor growth 
represent the ratio of the current tumor size to the initial size before the treatment was 
initiated. The data represent means ± SDs, p-values by one-way ANOVA. 
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Figure 17 Light microscopy (left) and TEM (right upper and lower) images of U251 
malignant tumor cells in the mouse 6 hours after the injection of HAMG-GNPs. GNPs are 
clustered in vacuoles as in U251MG cells in the experiments in vitro, being eligible for 
further radiosensitization. 
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Figure 18 Pathological analysis of the tumor samples after 3 injections of HAMG-NPs and 
radiotherapy, toluidine blue staining. GNPs are clearly seen in the cell population between the 
muscle fibers. The muscle fibers are clear from GNPs, showing potential selectivity of 
hyaluronic acid-coated GNPs.  
 
 
 
   
Table 1 Summary of radiobiological parameters for U251MG cells irradiated with 150 kVp X-rays with/without GNPs. α and β values derived from fitting 
the experiment data to the LQ model, SF=exp -(αD + βD2). SF2 dose represent the radiation dose for the cells with GNPs needed to obtain the same 
surviving fraction as 2 Gy irradiation given to the cells without GNPs, DEF (SF2) in the ratio of SF2 dose to 2 (Gy). P-values (SF2 fit.) were calculated from the 
fitted values of SF2. D10 is the dose needed to achieve 10% of cell survival, and DEF (D10) is the D10 ratio between the control and cells with GNPs. AUC is the 
area under the fitted LQ model curve; DEF (AUC) is the AUC ratio between the control and treatment groups. P-values (SF2 fit., D10, AUC) were calculated 
by one-way ANOVA. 
Parameter α[Gy-1] β [Gy-2] 
SF2 dose, 
Gy 
DEF (SF2) 
p-value 
(SF2 fit.) 
D10 DEF (D10) 
p-value 
(D10) 
AUC DEF (AUC) 
p-value 
(AUC) 
Control 
0.196 
±0.002 
0.027 
±0.0004 
2  
 6.132 
±0.694 
  
2.897 
±0.431 
  
8 
nm 
15 µg/ml 
0.314 
±0.002 
0.019 
±<0.0001 
1.463 1.367 0.208 
5.341 
±0.785 
1.148 0.081 
2.506 
±0.506 
1.156 0.169 
30 µg/ml 
0.340 
±0.059 
0.014 
±0.009 
1.391 1.438 0.183 
5.659 
±1.031 
1.084 0.321 
2.560 
±0.526 
1.132 0.237 
45 µg/ml 
0.306 
±0.017 
0.028 
±0.003 
1.443 1.386 0.065 
5.000 
±0.529 
1.226 0.012 
2.325 
±0.343 
1.246 0.036 
50 
nm 
15 µg/ml 
0.191 
±0.033 
0.048 
±0.006 
1.802 1.110 0.729 
5.157 
±0.313 
1.189 0.02 
2.595 
±0.368 
1.116 0.243 
30 µg/ml 
0.126 
±0.012 
0.079 
±0.003 
1.842 1.086 0.294 
4.428 
±0.307 
1.385 <0.001 
2.325 
±0.277 
1.246 0.032 
45 µg/ml 
0.240 
±0.014 
0.066 
±0.003 
1.481 1.350 0.082 
4.364 
±0.200 
1.405 <0.001 
2.197 
±0.216 
1.319 0.01 
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